Verastem Inc
$ 3.81
-9.07%
02 Jun - close price
- Market Cap 368,191,000 USD
- Current Price $ 3.81
- High / Low $ 4.25 / 3.79
- Stock P/E N/A
- Book Value 0.74
- EPS -2.52
- Next Earning Report f
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.59 %
- ROE -7.86 %
- 52 Week High 11.25
- 52 Week Low 3.79
About
Verastem, Inc., a developing-stage biopharmaceutical company focused on developing and commercializing life-enhancing drugs for cancer patients. The company is headquartered in Needham, Massachusetts.
Analyst Target Price
$16.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-04 | 2025-11-04 | 2025-08-07 | 2025-05-13 | 2025-03-20 | 2024-11-06 | 2024-08-08 | 2024-05-09 | 2024-03-14 | 2023-11-08 | 2023-08-08 |
| Reported EPS | -0.43 | -0.4592 | -1.35 | -0.62 | -0.79 | -0.6 | -0.6 | -0.31 | -1.26 | -1.02 | -0.75 | -1.37 |
| Estimated EPS | -0.4667 | -0.4967 | -0.87 | -0.88 | -0.775 | -0.7367 | -0.74 | -0.95 | -1 | -0.62 | -0.84 | -1.06 |
| Surprise | 0.0367 | 0.0375 | -0.48 | 0.26 | -0.015 | 0.1367 | 0.14 | 0.64 | -0.26 | -0.4 | 0.09 | -0.31 |
| Surprise Percentage | 7.8637% | 7.5498% | -55.1724% | 29.5455% | -1.9355% | 18.5557% | 18.9189% | 67.3684% | -26% | -64.5161% | 10.7143% | -29.2453% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | f |
| Fiscal Date Ending | o |
| Estimated EPS | r |
| Currency | m |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VSTM
2026-06-01 22:40:44
Verastem Inc (VSTM) shares on Nasdaq are holding steady around their late-May levels as investors evaluate the company's recent revenue update and strategic priorities for 2026. The stock closed at USD 4.33 on May 29, 2026, reflecting market assessment of its oncology pipeline and financial outlook. Investors are closely monitoring quarterly figures and upcoming clinical milestones for future price direction within the broader biotech sector.
2026-05-27 22:10:12
Verastem, Inc.'s new director, Michael P. Bailey, has filed an initial SEC Form 3, disclosing his beneficial ownership status. This filing officially establishes him as an insider for regulatory purposes but reports no current insider transactions or derivative positions. The document serves as a baseline for tracking his future holdings in the company.
2026-05-27 22:10:12
Verastem, Inc.'s director, Michael P. Bailey, was granted 108,000 restricted stock units (RSUs) as an equity award, comprising a 36,000-unit annual grant and a 72,000-unit initial grant under the company's 2021 Equity Incentive Plan. These RSUs will vest over time, with the annual grant vesting monthly from June 2026 to May 2027 and the initial grant vesting quarterly over three years, both contingent on Bailey's continued board service. Following this transaction, Bailey directly holds 108,000 shares/RSUs.
2026-05-27 21:10:12
This article reports on a Form 144 SEC filing by Verastem, Inc. (VSTM), dated May 27, 2026. The filing indicates a neutral impact and sentiment, detailing the proposed sale of 20,103 common shares acquired through vested restricted stock units on December 31, 2020. The aggregate market value of these shares is $87,649.08, with the sale to be executed through Jefferies LLC on the Nasdaq exchange.
2026-05-27 17:10:21
Verastem Oncology announced that its management team will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 8:10 am ET in New York. A live webcast of the chat will be available on the company's website, with a replay archived for approximately 90 days. Verastem Oncology focuses on developing and commercializing new medicines for patients with RAS/MAPK pathway-driven cancers.
2026-05-27 17:08:46
Verastem, Inc. director Brian M. Stuglik has been granted 36,000 restricted stock units (RSUs) as part of his compensation, which will vest in monthly installments from June 2026 through April 2027, provided he continues his board service. These RSUs were awarded at no cash cost and are not considered an open-market transaction. Following this grant, Stuglik directly holds 137,147 shares of Verastem Common Stock.
